Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
J Diabetes Investig. 2020 Sep;11(5):1159-1162. doi: 10.1111/jdi.13231. Epub 2020 Apr 2.
Cancer patients with diabetes experience a poorer prognosis, yet the population burden of this multimorbidity remains unknown. This study aimed to estimate the latest incidence and prevalence of cancer with diabetes mellitus in Japan. We used projection of cancer incidence and latest survival data from population-based cancer registries. The incidence of cancer associated with diabetes was estimated separately for patients with pre-existing diabetes and those without diabetes, and used to estimate the 5-year cancer prevalence for those with and without diabetes. The prevalence of pre-existing diabetes in cancer patients at any cancer site was estimated to be 20.7% (647,160 men and women). Among cancer sites, diabetes prevalence was high in patients with liver and pancreatic cancers in both sexes. In conclusion, our study shows a large burden of diabetes in cancer patients in Japan, which warrants further attention by health practitioners and policy-makers.
癌症合并糖尿病患者的预后较差，但这种共病的人群负担尚不清楚。本研究旨在估计日本癌症合并糖尿病的最新发病率和患病率。我们使用基于人群的癌症登记处的癌症发病率预测和最新生存数据。分别估计了患有和不患有糖尿病的患者中与糖尿病相关的癌症的发病率，并用于估计有和无糖尿病患者的 5 年癌症患病率。任何癌症部位的癌症患者中预先存在的糖尿病的患病率估计为 20.7%（男性和女性各 647,160 人）。在癌症部位中，男女肝癌和胰腺癌患者的糖尿病患病率较高。总之，我们的研究表明日本癌症患者中糖尿病负担沉重，这需要卫生保健提供者和政策制定者进一步关注。
